



Marinomed partners with Perrigo to distribute virus-blocking Carragelose nasal spray in Scandinavia and France

- Carragelose-containing nasal spray has been launched in Finland, Norway, Sweden and France by Perrigo in September and October 2021
- Perrigo is a strong partner, who is providing over-the-counter health and wellness solutions and will help to significantly boost Carragelose availability
- Carragelose-based products have been shown to effectively inactivate multiple respiratory viruses and are available without prescription in over 40 countries

Korneuburg, Austria, 27 October 2021 – Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that Marinomed and Perrigo Company plc (NYSE; TASE: PRGO) signed an agreement for the distribution of the virus blocker Carragelose® in Finland, Norway, Sweden and France. Perrigo has launched Carragelose under the trade names Physiomer® in Scandinavia and Phytosun Aroms® in France in September and October 2021. Carragelose products are already available without prescription over the counter (OTC) in more than 40 countries. Carragelose is highly efficient in preventing infection and viral spread of multiple respiratory viruses.

“We are proud to partner with Perrigo, an exceptionally experienced organization, to further extend the global reach of our virus blocker Carragelose. With the likely resurgence of respiratory diseases in the upcoming cold season, we are satisfied that Carragelose will be available to even more people providing them protection from viral respiratory infections,” said **Dr. Andreas Grassauer, CEO of Marinomed**. “The virus-blocking properties of Carragelose can make an important contribution to improving public health and to support hygiene measures against respiratory viruses.”

Anneleen Spooren, Vice President International R&D and Innovation at Perrigo, commented: “Marinomed has shown impressive data on the potential of Carragelose for prevention and self-medication of respiratory infections caused by multiple viruses. Carragelose provides an extremely good fit with our portfolio of effective self-care products. We are happy to now expand our portfolio with this clinically validated virus-blocking^{1,2} and hypertonic product that can provide a fast relief of the symptoms. We are convinced that with Marinomed, we have a strong and reliable science-based partner at our side.”

About Carragelose®:

Carragelose® is a sulfated polymer from red seaweed and a unique, broadly active virus-blocking compound. It is known as a gentle, effective, and safe prevention and treatment of various viral respiratory infections. Several clinical and preclinical studies have shown that Carragelose® forms a layer on the mucosa that entraps entering viruses, thereby inactivating them, and preventing them from infecting cells. Laboratory and clinical data have shown that Carragelose® can also inactivate SARS-CoV-2.^{3,4} Marinomed is the holder of the IP rights and

has licensed Carragelose® for marketing in Europe, Canada, Australia, and parts of Asia and Latin America. Marinomed's portfolio of Carragelose®-containing nasal sprays and oral products can be accessed at <https://www.carragelose.com/en/portfolio/launched-products>, scientific publications on Carragelose® at <https://www.carragelose.com/en/publications>.

About Marinomed Biotech AG

Marinomed Biotech AG (Korneuburg, Austria) (VSE:MARI) is an Austrian science-based biotech company with globally marketed therapeutics. The company is listed on the Prime Market of the Vienna Stock Exchange. Marinomed focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv® technology increases the solubility and bioavailability of compounds that are hardly soluble in aqueous formulations. The Carragelose® platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and may also reduce the risk of an infection with SARS-CoV-2. Carragelose® is used as a virus blocker in nasal sprays, throat sprays, and lozenges, which are sold via international partners in over 40 countries. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only. Further information is available at <https://www.marinomed.com>.

¹ <https://openvirologyjournal.com/VOLUME/14/PAGE/9/>

² <https://www.carragelose.com/en>

³ <https://www.dovepress.com/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article-IJGM>

⁴ <https://www.marinomed.com/en/news/marinomed-biotech-ag-shares-positive-clinical-trial-results-for-iota-carrageenan-nasal-spray-in-the-prevention-of-covid-19-1>

For further inquiries contact:

Marinomed Biotech AG

Lucia Mayr-Harting, PR
Hovengasse 25, 2100 Korneuburg, Austria
T +43 2262 90300 158
E-mail: pr@marinomed.com
<http://www.marinomed.com>

International Media and IR Contact

MC Services AG
Dr. Brigitte Keller, Dr. Regina Lutz
T +49 89 210228 0
UK: Shaun Brown
M: +44 7867 515 918
E-mail: marinomed@mc-services.eu

Disclaimer

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.